©The Author(s) 2022.
World J Clin Cases. Apr 6, 2022; 10(10): 3047-3059
Published online Apr 6, 2022. doi: 10.12998/wjcc.v10.i10.3047
Published online Apr 6, 2022. doi: 10.12998/wjcc.v10.i10.3047
Table 1 Characteristics of the patient cohort
| Characteristic | All patients (n = 325) | Survivornon-survivor (n = 308); (n = 17) | P value | |
| Age | < 0.0011 | |||
| Median (IQR)-yr | 45.0 (34.0-61.0) | 43.0 (33.0-61.0) | 63.0 (57.0-76.0) | |
| Distribution-no./total no. (%) | ||||
| 20-49 yr | 178 | 178 (57.8) | 0 (0.0) | |
| 50-64 yr | 91 | 80 (25.9) | 11 (64.7) | |
| ≥ 65 yr | 56 | 50 (16.2) | 6 (35.3) | |
| Male sex - no./total no. (%) | 137 (42.2) | 124 (40.3) | 13 (76.5) | 0.0031 |
| Smoking history - no./total no. (%) | 21 (6.5) | 18 (5.8) | 3 (17.7) | 0.054 |
| Exposure to source of transmission within past 14 days - no./total no. | 0.0351 | |||
| Yes | 233 (71.7) | 222 (4.9) | 11 (66.8) | |
| No | 92 (28.3) | 86 (0.3) | 6 (28.0) | |
| Median incubation period (IQR) - days | 5.0 ± 4.0 | 5.0 ± 3.9 | 5.2 ± 3.5 | 0.862 |
| Fever on admission | ||||
| Patients - no./total no. (%) | 252 (77.5) | 240 (77.9) | 12 (70.6) | 0.550 |
| Median temperature (IQR) - °C | ||||
| Distribution of temperature - no./total no. (%) | 0.603 | |||
| < 37.3 °C | 77 (23.7) | 72 (22.2) | 5 (1.5) | |
| 37.3-38.0 °C | 106 (32.6) | 103 (31.7) | 3 (0.9) | |
| 38.1-39.0 °C | 124 (38.2) | 116 (35.7) | 8 (2.5) | |
| > 39.0°C | 18 (5.5) | 17 (5.2) | 1 (0.3) | |
| Symptoms - no. (%) | ||||
| Conjunctival congestion | 1 (0.31) | 1 (0.31) | 0 (0.0) | 1.000 |
| Headache | 52 (16) | 51 (16.6) | 1 (5.9) | 0.243 |
| Cough | 207 (63.7) | 199 (64.6) | 8 (47.1) | 0.143 |
| Sputum production | 81 (24.9) | 76 (24.6) | 5 (29.4) | 0.660 |
| Fatigue | 156 (48) | 145 (47.1) | 11 (64.7) | 0.157 |
| Difficulty breathing | 15 (4.6) | 13 (4.2) | 2 (11.8) | 0.149 |
| Shortness of breath | 73 (22.5) | 68 (22.1) | 5 (29.4) | 0.0121 |
| Nausea or vomiting | 25 (7.7) | 21 (6.8) | 4 (23.5) | 0.0121 |
| Diarrhea | 28 (8.6) | 27 (8.8) | 1 (5.9) | 0.680 |
| Myalgia or arthralgia | 92 (28.3) | 88 (28.5) | 4 (23.5) | 0.630 |
| Chills | 55 (16.9) | 54 (17.5) | 1 (5.88) | 0.212 |
| Coexisting disorder - no. (%) | ||||
| Fatty liver | 15 (4.6) | 15 (4.9) | 0 (0) | 1.000 |
| Chronic obstructive pulmonary disease | 17 (5.2) | 16 (5.2) | 1 (5.9) | 0.608 |
| Diabetes | 34 (10.5) | 27 (8.77) | 7 (41.2) | < 0.0011 |
| Hypertension | 69 (21.2) | 58 (18.8) | 11 (64.7) | < 0.0011 |
| Coronary heart disease | 9 (2.8) | 6 (1.9) | 3 (17.7) | < 0.0011 |
| Cerebrovascular disease | 18 (5.5) | 14 (4.6) | 4 (23.5) | 0.0101 |
| Hyperlipidemia | 17 (5.2) | 16 (5.2) | 1 (5.8) | 0.901 |
| Hepatitis B infection | 6 (1.9) | 5 (1.6) | 1 (5.9) | 0.205 |
- Citation: Zhao SC, Yu XQ, Lai XF, Duan R, Guo DL, Zhu Q. Dose-response relationship between risk factors and incidence of COVID-19 in 325 hospitalized patients: A multicenter retrospective cohort study. World J Clin Cases 2022; 10(10): 3047-3059
- URL: https://www.wjgnet.com/2307-8960/full/v10/i10/3047.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i10.3047